These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

617 related articles for article (PubMed ID: 31134762)

  • 21. Clinical validation of the detection of KRAS and BRAF mutations from circulating tumor DNA.
    Thierry AR; Mouliere F; El Messaoudi S; Mollevi C; Lopez-Crapez E; Rolet F; Gillet B; Gongora C; Dechelotte P; Robert B; Del Rio M; Lamy PJ; Bibeau F; Nouaille M; Loriot V; Jarrousse AS; Molina F; Mathonnet M; Pezet D; Ychou M
    Nat Med; 2014 Apr; 20(4):430-5. PubMed ID: 24658074
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Circulating tumor DNA in patients with colorectal adenomas: assessment of detectability and genetic heterogeneity.
    Myint NNM; Verma AM; Fernandez-Garcia D; Sarmah P; Tarpey PS; Al-Aqbi SS; Cai H; Trigg R; West K; Howells LM; Thomas A; Brown K; Guttery DS; Singh B; Pringle HJ; McDermott U; Shaw JA; Rufini A
    Cell Death Dis; 2018 Aug; 9(9):894. PubMed ID: 30166531
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Evaluation of KRAS, NRAS and BRAF mutations detection in plasma using an automated system for patients with metastatic colorectal cancer.
    Franczak C; Witz A; Geoffroy K; Demange J; Rouyer M; Husson M; Massard V; Gavoille C; Lambert A; Gilson P; Gambier N; Scala-Bertola J; Merlin JL; Harlé A
    PLoS One; 2020; 15(1):e0227294. PubMed ID: 31940389
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Liquid biopsy-based tumor profiling for metastatic colorectal cancer patients with ultra-deep targeted sequencing.
    Kang JK; Heo S; Kim HP; Song SH; Yun H; Han SW; Kang GH; Bang D; Kim TY
    PLoS One; 2020; 15(5):e0232754. PubMed ID: 32379795
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Comparative analysis of real-time quantitative PCR-Sanger sequencing method and TaqMan probe method for detection of KRAS/BRAF mutation in colorectal carcinomas].
    Zhang X; Wang Y; Gao N; Wang J
    Zhonghua Bing Li Xue Za Zhi; 2014 Feb; 43(2):77-82. PubMed ID: 24742565
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Multiplex detection of ctDNA mutations in plasma of colorectal cancer patients by PCR/SERS assay.
    Lyu N; Rajendran VK; Diefenbach RJ; Charles K; Clarke SJ; Engel A; ; Rizos H; Molloy MP; Wang Y
    Nanotheranostics; 2020; 4(4):224-232. PubMed ID: 32923312
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cell-free DNA as biomarker and source for mutation detection in primary colorectal cancer.
    Nikolic A; Vlajnic M; Ristanovic M; Petrovic J; Dimitrijevic I; Krivokapic Z; Radojkovic D
    J BUON; 2017; 22(1):178-183. PubMed ID: 28365952
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Combined mutational analysis of KRAS, NRAS and BRAF genes in Indian patients with colorectal carcinoma.
    Bagadi SB; Sanghvi M; Nair SB; Das BR
    Int J Biol Markers; 2012; 27(1):27-33. PubMed ID: 22427190
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The Clinical Impact of Quantitative Cell-free DNA, KRAS, and BRAF Mutations on Response to Anti-EGFR Treatment in Patients with Metastatic Colorectal Cancer.
    Moradi-Marjaneh R; Asgharzadeh F; Khordad E; Marjaneh MM
    Curr Pharm Des; 2021; 27(7):942-952. PubMed ID: 33030125
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Enumeration and targeted analysis of KRAS, BRAF and PIK3CA mutations in CTCs captured by a label-free platform: Comparison to ctDNA and tissue in metastatic colorectal cancer.
    Kidess-Sigal E; Liu HE; Triboulet MM; Che J; Ramani VC; Visser BC; Poultsides GA; Longacre TA; Marziali A; Vysotskaia V; Wiggin M; Heirich K; Hanft V; Keilholz U; Tinhofer I; Norton JA; Lee M; Sollier-Christen E; Jeffrey SS
    Oncotarget; 2016 Dec; 7(51):85349-85364. PubMed ID: 27863403
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Circulating tumor cell free DNA from plasma and urine in the clinical management of colorectal cancer.
    Yu H; Han L; Yuan J; Sun Y
    Cancer Biomark; 2020; 27(1):29-37. PubMed ID: 31658042
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Identification of liquid biopsy-based mutations in colorectal cancer by targeted sequencing assays.
    Szász I; Kiss T; Mokánszki A; Koroknai V; Deák J; Patel V; Jámbor K; Ádány R; Balázs M
    Mol Cell Probes; 2023 Feb; 67():101888. PubMed ID: 36513244
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Circulating tumor DNA-based early detection of precancerous colorectal lesions using QClamp XNA-mediated real-time PCR.
    Chen S; Wang Y; Wang K; Zhang L; Zhang X
    Pharmazie; 2021 Dec; 76(12):606-610. PubMed ID: 34986957
    [TBL] [Abstract][Full Text] [Related]  

  • 34. High prevalence of mutant KRAS in circulating exosome-derived DNA from early-stage pancreatic cancer patients.
    Allenson K; Castillo J; San Lucas FA; Scelo G; Kim DU; Bernard V; Davis G; Kumar T; Katz M; Overman MJ; Foretova L; Fabianova E; Holcatova I; Janout V; Meric-Bernstam F; Gascoyne P; Wistuba I; Varadhachary G; Brennan P; Hanash S; Li D; Maitra A; Alvarez H
    Ann Oncol; 2017 Apr; 28(4):741-747. PubMed ID: 28104621
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Liquid biopsy-based analysis by ddPCR and CAPP-Seq in melanoma patients.
    Kaneko A; Kanemaru H; Kajihara I; Mijiddorj T; Miyauchi H; Kuriyama H; Kimura T; Sawamura S; Makino K; Miyashita A; Aoi J; Makino T; Masuguchi S; Fukushima S; Ihn H
    J Dermatol Sci; 2021 Jun; 102(3):158-166. PubMed ID: 34049769
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prospective blinded study of somatic mutation detection in cell-free DNA utilizing a targeted 54-gene next generation sequencing panel in metastatic solid tumor patients.
    Kim ST; Lee WS; Lanman RB; Mortimer S; Zill OA; Kim KM; Jang KT; Kim SH; Park SH; Park JO; Park YS; Lim HY; Eltoukhy H; Kang WK; Lee WY; Kim HC; Park K; Lee J; Talasaz A
    Oncotarget; 2015 Nov; 6(37):40360-9. PubMed ID: 26452027
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Revolutionizing Non-Small Cell Lung Cancer Diagnosis: Ultra-High-Sensitive ctDNA Analysis for Detecting Hotspot Mutations with Long-term Stored Plasma.
    Lee JY; Jeon S; Jun HR; Sung CO; Jang SJ; Choi CM; Chun SM
    Cancer Res Treat; 2024 Apr; 56(2):484-501. PubMed ID: 37871897
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Surface Enhanced Raman Spectroscopy (SERS) for the Multiplex Detection of Braf, Kras, and Pik3ca Mutations in Plasma of Colorectal Cancer Patients.
    Li X; Yang T; Li CS; Song Y; Lou H; Guan D; Jin L
    Theranostics; 2018; 8(6):1678-1689. PubMed ID: 29556349
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Detection of KRAS mutations in liquid biopsies from metastatic colorectal cancer patients using droplet digital PCR, Idylla, and next generation sequencing.
    Holm M; Andersson E; Osterlund E; Ovissi A; Soveri LM; Anttonen AK; Kytölä S; Aittomäki K; Osterlund P; Ristimäki A
    PLoS One; 2020; 15(11):e0239819. PubMed ID: 33237900
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Analysis of Circulating Tumor DNA in Synchronous Metastatic Colorectal Cancer at Diagnosis Predicts Overall Patient Survival.
    Sayagués JM; Montero JC; Jiménez-Pérez A; Del Carmen S; Rodríguez M; Vidal Tocino R; Montero E; Sanz J; Abad M
    Int J Mol Sci; 2023 May; 24(9):. PubMed ID: 37176143
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 31.